Renalytix Plc ADR (NASDAQ: RNLX): How To Buy And When To Buy And Its Performance & Trends

EVTL

In the latest trading session,, 0.67 million Renalytix Plc ADR (NASDAQ:RNLX) shares changed hands as the company’s beta touched 2.78. With the company’s most recent per share price at $0.36 changed hands at -$0.05 or -11.62% at last look, the market valuation stands at $29.78M. RNLX’s current price is a discount, trading about -772.22% off its 52-week high of $3.14. The share price had its 52-week low at $0.22, which suggests the last value was 38.89% up since then. When we look at Renalytix Plc ADR’s average trading volume, we note the 10-day average is 0.22 million shares, with the 3-month average coming to 1.95 million.

Analysts gave the Renalytix Plc ADR (RNLX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended RNLX as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Renalytix Plc ADR’s EPS for the current quarter is expected to be -0.05.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Renalytix Plc ADR (NASDAQ:RNLX) trade information

Instantly RNLX was in red as seen in intraday trades today. With action -12.40%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -7.95%, with the 5-day performance at -12.40% in the red. However, in the 30-day time frame, Renalytix Plc ADR (NASDAQ:RNLX) is 20.19% up. Looking at the short shares, we see there were 0.52 million shares sold at short interest cover period of 0.11 days.

The consensus price target for the stock as assigned by Wall Street analysts is 2, meaning bulls need an upside of 82.0% from its recent market value. According to analyst projections, RNLX’s forecast low is 2 with 2 as the target high. To hit the forecast high, the stock’s price needs a -455.56% plunge from its current level, while the stock would need to soar -455.56% for it to hit the projected low.

Renalytix Plc ADR (RNLX) estimates and forecasts

Data shows that the Renalytix Plc ADR share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -52.13% over the past 6 months, a 40.00% in annual growth rate that is considerably higher than the industry average of 10.90%. Year-over-year growth is forecast to reach -26.50% down from the last financial year.

Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 800k. 2 analysts are of the opinion that Renalytix Plc ADR’s revenue for the current quarter will be 900k. The company’s revenue for the corresponding quarters a year ago was 518k and 700k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 54.40%. The estimates for the next quarter sales put growth at 28.60%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -134.94%. The 2024 estimates are for Renalytix Plc ADR earnings to increase by 12.87%.

RNLX Dividends

Renalytix Plc ADR is expected to release its next quarterly earnings report in September.

Renalytix Plc ADR (NASDAQ:RNLX)’s Major holders

PINNACLE ASSOCIATES LTD holds the second largest percentage of outstanding shares, with 1.4311% or 0.7 million shares worth $0.6 million as of 2024-03-31.

With 4.87 shares estimated at $1719.0 under it, the former controlled 0.01% of total outstanding shares.